跳到正文
原文
Medical Xpress·· 23 天前精选AI 评分63

JAMA发表随机双盲试验,单次鼻喷mebufotenin苯甲酸盐改善难治性抑郁

Single dose of fast-acting psychedelic nasal spray shows promise for stubborn depression

AI 导读

一项发表于JAMA的随机双盲试验纳入193例难治性抑郁成人,单次鼻喷mebufotenin苯甲酸盐8 mg或12 mg后,78%至85%的受试者在2小时内达到离院标准。

推荐理由

193例难治性抑郁患者的随机双盲试验同时报告2小时内离院比例与4周评分变化,可供评估短效致幻剂的给药模式。

正文
Psychedelic Nasal Spray
Credit: Image generated by the editorial team using AI for illustrative purposes.

One in three individuals with major depressive disorder does not get relief from standard daily antidepressant medications. The up-and-coming psychedelic therapeutics like psilocybin or LSD do show promise of quick relief, even for difficult-to-treat depression. The psychedelic effects, however, are often strong and linger for a long time, requiring patients to remain under medical supervision in a clinic for four to 12 hours.

A recent study published in JAMA investigated whether intranasal mebufotenin benzoate, known for its brief but fast-acting psychedelic experiences, could be a solution to this problem. The researchers enrolled adults ages 18 to 75 with treatment-resistant depression across 38 clinical sites in the U.S., Australia and Europe. In a comfortable clinical room, a clinician delivered a single spray into one nostril, and that one puff delivered one of three possible doses of the drug.

Regardless of whether participants received the low, medium or high dose, the spray's effects wore off quickly. Across the three dose groups, 78% to 85% of participants were considered ready for discharge within two hours of receiving the drug. Even though the psychedelic effects faded within hours, the relief didn't. After a single medium or high dose, depression symptoms began to ease within a day, and the improvement held for up to eight weeks.

No more waiting around

Major depressive disorder is a debilitating condition that can happen to anyone and wreak havoc on one's mood and quality of life. It is more than feeling sad; it can drain joy from activities a person once loved, leave them grappling with profound sadness or despair, or make them unusually irritable. These spells aren't always temporary, as they can go on for weeks and even months.

Approximately 33% of people with major depressive disorder have treatment-resistant depression, where standard antidepressants fail to bring them relief. People living with this form of MDD can experience a lower quality of life, intensified emotional distress and increased suicide risk. In recent years, scientists have found some hope with psychedelic therapeutics, where even a single treatment has shown positive outcomes.

However, opting for such treatments goes hand in hand with spending half a day or a full day in a clinical facility for every treatment session due to the prolonged altered state of awareness induced by psychedelics. This can create logistical hurdles that can further limit access to treatment.

Mebufotenin benzoate is a short-acting psychedelic formulated as a nasal spray. Once in the brain, the drug binds to and activates two key serotonin receptors, 5-HT1A and 5-HT2A, which help regulate mood and perception.

To find out if this fast-acting compound could deliver rapid and durable antidepressant relief while allowing most patients to go home safely within two hours, the researchers enrolled 193 adults with moderate-to-severe major depressive disorder. Every participant had treatment-resistant depression, having already tried between two and five antidepressant treatments during their current episode without success.

Participants were randomly assigned to receive one of three doses of mebufotenin benzoate—12 mg, 8 mg or a 0.3 mg low dose designed to maintain blinding. Neither participants, clinic staff nor the researchers assessing changes in depression symptoms knew which dose each person received.

Short-term psychedelic, long-term therapeutic

Ninety minutes after they received their nasal spray dose, clinic staff formally assessed participants' readiness for discharge every 30 minutes based on safety and recovery criteria. They found that 85% of participants in the 8 mg group and 78% in the 12 mg group met all safety criteria and were ready to be discharged from the clinic within two hours.

Following the participants for weeks to come revealed that a single dose of mebufotenin benzoate, at either 8 mg or 12 mg, produced rapid and lasting improvements in treatment-resistant depression.

Four weeks later, the 12 mg dose had lowered clinician-rated depression scores by about five points more than the low-dose control on a 60-point scale; the 8 mg dose also performed similarly. Roughly one-third of participants who received either higher dose saw their symptom scores fall by at least half.

The results demonstrated that a prolonged psychedelic effect is not required for a durable, long-lasting antidepressant effect. Future studies with longer observation periods are needed to establish how long benefits last and whether repeat dosing is needed.

Written for you by our author Sanjukta Mondal, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.

Publication details

David Feifel et al., Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression, JAMA (2026). DOI: 10.1001/jama.2026.18380

Chittaranjan Andrade, Treatment Approach to Major Depressive Disorder, JAMA (2026). DOI: 10.1001/jama.2026.17333

Journal information: Journal of the American Medical Association

Key medical concepts

Depression, Emotional

Who's behind this story?

Sanjukta Mondal

Sanjukta Mondal

Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

© 2026 Science X Network

Citation: Single dose of fast-acting psychedelic nasal spray shows promise for stubborn depression (2026, October 28) retrieved 28 October 2026 from https://medicalxpress.com/news/2026-10-dose-fast-psychedelic-nasal-spray.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com